Insomnia, daytime sleepiness and cardio-cerebrovascular diseases in the elderly: a 6-year prospective study
To examine 1) the associations between history of cardio-cerebrovascular diseases (CVD) and insomnia complaints and excessive daytime sleepiness (EDS), and 2) the relationships between sleep complaints and future CVD in persons over 65. CVD was assessed at baseline and during two, four, and six-year...
Saved in:
Published in | PloS one Vol. 8; no. 2; p. e56048 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Public Library of Science
14.02.2013
Public Library of Science (PLoS) |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | To examine 1) the associations between history of cardio-cerebrovascular diseases (CVD) and insomnia complaints and excessive daytime sleepiness (EDS), and 2) the relationships between sleep complaints and future CVD in persons over 65.
CVD was assessed at baseline and during two, four, and six-year follow-up in 5494 non-demented subjects. Self-reported insomnia complaints (poor sleep quality, difficulty in initiating sleep, difficulty in maintening sleep, and early morning awakening), EDS and sleep medication use were evaluated at baseline. Logistic regression models and Cox proportional hazard models, with delayed entry and age of participants as the time scale, were adjusted for socio-demographic, lifestyle and clinical variables.
At baseline, 748 participants had a past-history of CVD. A past-history of CVD was associated with EDS (OR = 1.28 95%CI = [1.05-1.57]) and the number of insomnia complaints (OR = 1.26 95%CI = [1.03-1.55] for 1-2 insomnia complaints; OR = 1.32 95%CI = [1.03-1.71] for ≥3 complaints). In longitudinal analyses, neither the four components of insomnia nor the number of insomnia complaints were significantly associated with first or recurrent CVD events (n = 391 events). EDS was independently associated with future CVD events even after adjusting for prescribed sleep medication and past-history of CVD (HR = 1.35 95%CI = [1.06-1.71]).
Our results suggest that the relationships between sleep complaints and CVD could be complex. Insomnia complaints are more likely a consequence of CVD, whereas EDS appears to be a determinant of CVD independently of past-history of CVD. EDS screening may thus constitute a means of detecting persons at high risk of CVD. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Revised the manuscript: CH CT KR. Conceived and designed the experiments: IJ JB YD. Performed the experiments: IJ MLA YD. Analyzed the data: IJ JPE MLA AB JB YD. Contributed reagents/materials/analysis tools: IJ JB MLA YD. Wrote the paper: IJ YD. Competing Interests: Isabelle Jaussent, Dr. Jean Bouyer, Dr. Marie-Laure Ancelin, Dr. Catherine Helmer and Dr. Alain Besset report no disclosures. Dr. Jean-Philippe Empana has received consultancy honoraria from Lundbeck and speaker honoraria from Pfizer. Dr. Karen Ritchie serves on scientific advisory boards for the Biomedical Research Centre, King’s College London, and MRC Strategic Steering Committee (Longitudinal Health and Aging Research Unit); and serves on the editorial advisory boards of the International Journal of Geriatric Psychiatry, Dementia, International Psychogeriatrics, Journal of Clinical and Experimental Gerontology, Psychogeriatrics, Neuronale, Neurologie-Psychiatrie-Gériatrie, and Gerontology. Dr. Christophe Tzourio has received fees from the Fondation Plan Alzheimer, the Fondation de Recherche sur l’Hypertension Artérielle, and the ABBOTT company for participating in scientific committees. He has also received investigator-initiated research funding from the French National Research Agency (ANR) and the Fondation Plan Alzheimer for the 3C study. He serves on the editorial advisory board of Neuroepidemiology, Journal of Hypertension, and Journal of Alzheimer’s disease. Pr. Yves Dauvilliers has received funds for speaking and board engagements with UCB pharma, Cephalon, Jazz, Novartis, and Bioprojet. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials. |
ISSN: | 1932-6203 1932-6203 |
DOI: | 10.1371/journal.pone.0056048 |